[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.166.112.64. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 403
Citations 0
Medical News and Perspectives
April 17, 2013

Two Specialty Societies to Run Their Own Clinical Trial of Heart Valve Replacement

JAMA. 2013;309(15):1575-1576. doi:10.1001/jama.2013.2789

The American College of Cardiology (ACC) and the Society of Thoracic Surgeons (STS) will conduct a clinical trial exploring the safety and efficacy of expanded uses of transcatheter aortic valve replacement (TAVR) in certain types of patients with severe aortic stenosis. The trial is believed to be the first for any medical specialty societies.

Aortic stenosis is a long-developing condition that, once symptoms emerge, is highly lethal. Roughly half of all untreated patients die in the first 2 years after symptoms appear. Surgical replacement of the valve reduces symptoms and improves survival, but at least 30% of patients with severe symptoms do not undergo surgery because of advanced age (most patients who develop symptoms are older than 80 years), left ventricular dysfunction, or comorbid conditions.

First Page Preview View Large
First page PDF preview
First page PDF preview
×